Crossmark

Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

Crossref DOI link: https://doi.org/10.1186/s13046-024-03149-x

Published Online: 2024-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ciccioli, Mariacristina http://orcid.org/0009-0000-2518-0878
Kim, Kyukwang

Khazan, Negar

Khoury, Joseph D

Cooke, Martin J

Miller, M Craig

O’Shannessy, Daniel J

Pailhes-Jimenez, Anne-Sophie

Moore, Richard G
License Information

Text and Data Mining valid from 2024-08-21

Version of Record valid from 2024-08-21
More Information

Article History

Received: 3 May 2024

Accepted: 3 August 2024

First Online: 21 August 2024

Declarations

:

: The ANG-008 study was approved by the University of Rochester’s Office for Human Subject Protection Research Subject Review Board (FWA00009386, IRB reference STUDY00003288, CTO# IBRS18143), and all participants provided written informed consent prior to enrollment into the study. See Methods for more details.

: Not applicable.

: Authors MC, MJC, MCM and ASPJ are employees of ANGLE. DJO was an employee at ANGLE. JDK has received honoraria as an ANGLE Scientific Advisor.

Document is current

Any future updates will be listed below